GSGianmarco Sabiu

Gianmarco Sabiu

*This is an algorithmically generated author record based on publicly available information.

Gianmarco Sabiu has a total of 50 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance

    by Yanjia Che, Yuta Yamamura, Sungwook Jung, Gianmarco Sabiu, Shameer M. Kondengadan, Stephani Edwina Lucia, Yang Song, Hayeon Byun, Xiaofei Li, Andy J. Seelam, et al.

    BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN known as high endothelial venules (HEVs) mediate this process. HEVs express a key glycoprotein containing 6-sulfo sialyl Lewis X, the binding site for L-selectin on the membrane of naive T cells. The proper formation of this carbohydrate requires sulfation by N-acetylglucosamine 6-O-sulfotransferases, particularly CHST4. Given the critical role of CHST4 in HEVs and transplant immunity, we aimed to develop a first-in-class antibody-drug conjugate (ADC) targeting the CHST4/HEV axis to deliver immunoregulatory therapeutics to LNs and promote long-term cardiac transplant survival. METHODS: We used CHST4 knockout mice and inducible diphtheria toxin receptor mouse models to investigate the role of CHST4 in HEV function during heart allograft transplantation. To assess the impact of CHST4 deficiency on heart transplant outcomes, we used fully major histocompatibility complex–mismatched and single major histocompatibility complex class II–mismatched models to study acute and chronic heart transplant rejection, respectively. We developed a first-in-class, dual-payload antibody-drug conjugate aimed at promoting regulatory T cells by conjugating rapamycin and tubastatin A to the HEV-targeting MHA112 antibody. The efficacy of this ADC was tested in murine heart allograft models. RESULTS: Loss of CHST4 expression by HEVs impaired the entry of naive T cells into LNs and consequently reduced regulatory T cell formation, thereby disrupting cardiac transplant acceptance under costimulatory blockade. Treatment with the HEV-targeted ADC carrying rapamycin and tubastatin A prolonged murine heart allograft survival and suppressed chronic rejection, a major barrier to long-term graft success. Mechanistically, this ADC enhanced regulatory T cell induction, reduced proinflammatory T cells within lymph nodes, and decreased immune cell infiltration in cardiac allografts, achieving these effects with substantially lower doses of rapamycin and tubastatin A compared with administration of the free drugs. CONCLUSIONS: Our findings uncover a key mechanistic role for CHST4 in HEVs in facilitating the regulatory T cell generation within the LN and promoting heart transplant acceptance. Moreover, we introduce a promising CHST4-based, HEV-targeted ADC therapy as a potential strategy to suppress heart transplant rejection.


  • Open Access

    CXCL12+ fibroblastic reticular cells in lymph nodes facilitate immune tolerance by regulating T cell–mediated alloimmunity

    by Yuta Yamamura, Gianmarco Sabiu, Jing Zhao, Sungwook Jung, Andy J. Seelam, Xiaofei Li, Yang Song, Marina W. Shirkey, Lushen Li, Wenji Piao, et al.

    Fibroblastic reticular cells (FRCs) are the master regulators of the lymph node (LN) microenvironment. However, the role of specific FRC subsets in controlling alloimmune responses remains to be studied. Single-cell RNA sequencing (scRNA-Seq) of naive and draining LNs (DLNs) of heart-transplanted mice and human LNs revealed a specific subset of CXCL12 hi FRCs that expressed high levels of lymphotoxin-β receptor (LTβR) and are enriched in the expression of immunoregulatory genes. CXCL12 hi FRCs had high expression of CCL19, CCL21, indoleamine 2,3-dioxygenase (IDO), IL-10, and TGF-β1. Adoptive transfer of ex vivo–expanded FRCs resulted in their homing to LNs and induced immunosuppressive environments in DLNs to promote heart allograft acceptance. Genetic deletion of LT β R and Cxcl12 in FRCs increased alloreactivity, abrogating the effect of costimulatory blockade in prolonging heart allograft survival. As compared with WT recipients, CXCL12 + FRC–deficient recipients exhibited increased differentiation of CD4 + T cells into Th1 cells. Nano delivery of CXCL12 to DLNs improved allograft survival in heart-transplanted mice. Our study highlights the importance of DLN CXCL12 hi FRCs in promoting transplant tolerance.


  • Open Access

    Magnetic Resonance Visibility, Artifacts, and Overall Safety of the Self-Locating Peritoneal Dialysis Catheter with a Tungsten Tip

    by Maurizio Gallieni, Umberto G. Rossi, Massimo Tonolini, Andrea Ianniello, Roberta Miglio, Gianmarco Sabiu, Maurizio Cariati

    Background. The self-locating peritoneal dialysis (PD) catheter, contains a tungsten tip. The effects of magnetic resonance (MR) on the catheter were evaluated, emphasizing its MR signal, artifacts, ferromagnetism, and possible heating production during the MR sequences. Methods. The catheter was studied in an ex vivo model using a 1.5TMR system and placed into a plastic box containing saline solution. Acquisitions on coronal and axial planes were obtained on fast gradient-echo T1-weighted and fast spin-echo T2-weighted. In vivo abdominal MR exams were also carried out. Results. Overall, the catheter had good visibility. In all sequences, an extensive paramagnetic blooming artifact was detected at the level of the tip tungsten ballast, with a circular artifact of 5cm in diameter. The catheter showed no magnetic deflection, rotation, or movements during all MR sequences. After imaging, the temperature of the saline solution did not change compared to the basal measurement. Patients safely underwent abdominal MR. Conclusions. The results point to the possibility of safely performing MR in PD patients carrying the self-locating catheter. The self-locating PD catheter is stable when subjected to a 1.5TMR system. However, it creates some visual interference, preventing an accurate study of the tissues surrounding the tungsten tip.


  • Open Access

    Delivery of costimulatory blockade to lymph nodes promotes transplant acceptance in mice

    by Jing Zhao, Sungwook Jung, Xiaofei Li, Lushen Li, Vivek Kasinath, Hengcheng Zhang, Said N. Movahedi, Ahmad Mardini, Gianmarco Sabiu, Yoonha Hwang, et al.

    The lymph node (LN) is the primary site of alloimmunity activation and regulation during transplantation. Here, we investigated how fibroblastic reticular cells (FRCs) facilitate the tolerance induced by anti-CD40L in a murine model of heart transplantation. We found that both the absence of LNs and FRC depletion abrogated the effect of anti-CD40L in prolonging murine heart allograft survival. Depletion of FRCs impaired homing of T cells across the high endothelial venules (HEVs) and promoted formation of alloreactive T cells in the LNs in heart-transplanted mice treated with anti-CD40L. Single-cell RNA sequencing of the LNs showed that anti-CD40L promotes a Madcam1+ FRC subset. FRCs also promoted the formation of regulatory T cells (Tregs) in vitro. Nanoparticles (NPs) containing anti-CD40L were selectively delivered to the LNs by coating them with MECA-79, which binds to peripheral node addressin (PNAd) glycoproteins expressed exclusively by HEVs. Treatment with these MECA-79–anti-CD40L-NPs markedly delayed the onset of heart allograft rejection and increased the presence of Tregs. Finally, combined MECA-79–anti-CD40L-NPs and rapamycin treatment resulted in markedly longer allograft survival than soluble anti-CD40L and rapamycin. These data demonstrate that FRCs are critical to facilitating costimulatory blockade. LN-targeted nanodelivery of anti-CD40L could effectively promote heart allograft acceptance.


  • Targeted nanotherapy for kidney diseases: a comprehensive review

    by Gianmarco Sabiu, Vivek Kasinath, Sungwook Jung, Xiaofei Li, George C Tsokos, Reza Abdi

    Kidney diseases represent a major public health problem, affecting millions of people worldwide. Moreover, the treatment of kidney diseases is burdened by the problematic effects of conventional drug delivery, such as systemic drug toxicity, rapid drug clearance, and the absence of precise targeting of the kidney. Although the use of nanotechnology in medicine is in its early stage and lacks robust translational studies, nanomedicines have already shown great promise as novel drug-delivery systems for the treatment of kidney disease. On the basis of our current knowledge of renal anatomy and physiology, pathophysiology of kidney diseases, and physicochemical characteristics of nanoparticles, an expansive repertoire and wide use of nanomedicines could be developed for kidney diseases in the near future. Some limitations have slowed the transition of these agents from preclinical studies to clinical trials, however. In this review, we summarize the current knowledge on renal drug-delivery systems and recent advances in renal cell targeting; we also demonstrate their important potential as future paradigm-shifting therapies for kidney diseases.